Diabetes Therapeutics Market by Product [Injectables] - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • ID: 4403190
  • Report
  • Region: Global
  • 170 pages
  • Allied Analytics LLP
1 of 3
The global diabetes therapeutics market was valued at $66,993 million in 2016, and is estimated to reach $186,842 million by 2023, growing at a CAGR of 16.0% from 2017 to 2023. Diabetes therapeutics are drugs used by diabetic patients to restore the blood glucose metabolism to a normal state.

The factors that drive the global diabetes therapeutics market include rise in geriatric population, increase in prevalence of diabetes worldwide, sedentary lifestyle of people, development of affordable & effective diabetes therapeutics, growth in awareness among people about self-management of diabetes, and support from the government However, side effects of diabetic drugs and stringent approval process for the same restrict the market growth. Moreover, surge in awareness about diabetes care and market potential in developing regions are expected to provide numerous opportunities for market growth.

The global diabetes therapeutics market is segmented on the basis of product and region. Based on product, it is bifurcated into injectable and oral-antidiabetic drugs (OAD). Injectable are further categorized into insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, and amylinomimetic drug. Oral-antidiabetic drugs (OAD) segment is further divided into biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, dipeptidyl peptidase IV (DPP-4) inhibitors, meglitinides, and sodium-glucose cotransporter-2 (SGLT2) inhibitors. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets.
Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale are provided.
Key market players are profiled and their strategies are analyzed thoroughly, which help understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

BY PRODUCT

Injectables
Insulin
Glucagon-like Peptide-1 (GLP-1) Receptor Agonists/Incretin Mimetics
Amylin Analogue/Amylinomimetic Drugs
Oral-antidiabetic Drugs (OAD)
Biguanides
Sulfonylureas
Thiazolidinediones
Alpha-glucosidase Inhibitors
Dipeptidyl Peptidase IV (DPP-4) Inhibitors/Gliptins
Meglitinides
Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors/Gliflozins

BY REGION

North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Spain
Italy
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

AstraZeneca plc
Boehringer Ingelheim GmbH
Eli Lilly and Company
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Novo Nordisk
Sanofi S.A.
Takeda Pharmaceutical Company Limited

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)

Astellas Pharma Inc.
Biocon Limited
Diasome Pharmaceuticals, Inc.
Generex Biotechnology Corp.
MannKind Corporation
Pfizer Inc.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.2.2.1. Competitive intelligence of companies and their strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. MARKET DYNAMICS

3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.4.4. Impact analysis

3.5. CLINICAL TRIALS

CHAPTER 4 GLOBAL DIABETES THERAPEUTICS MARKET, BY PRODUCT

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. INJECTABLES

4.2.1. Insulin

4.2.1.1. Market size and forecast

4.2.2. Glucagon-like peptide-1 (GLP-1) receptor agonists

4.2.2.1. Market size and forecast

4.2.3. Amylinomimetic drug

4.2.3.1. Market size and forecast

4.2.4. Key market trends
4.2.5. Growth factors and opportunities
4.2.6. Market size and forecast

4.3. ORAL-ANTIDIABETIC DRUGS (OAD)

4.3.1. Biguanides

4.3.1.1. Market size and forecast

4.3.2. Sulfonylureas

4.3.2.1. Market size and forecast

4.3.3. Thiazolidinediones

4.3.3.1. Market size and forecast

4.3.4. Alpha-glucosidase inhibitors

4.3.4.1. Market size and forecast

4.3.5. Dipeptidyl Peptidase IV (DPP-4) inhibitors

4.3.5.1. Market size and forecast

4.3.6. Meglitinides

4.3.6.1. Market size and forecast

4.3.7. Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors

4.3.7.1. Market size and forecast

4.3.8. Key market trends
4.3.9. Growth factors and opportunities
4.3.10. Market size and forecast

CHAPTER 5 DIABETES THERAPEUTICS MARKET, BY REGION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. NORTH AMERICA

5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast
5.2.4. U.S.
5.2.5. Canada
5.2.6. Mexico

5.3. EUROPE

5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast
5.3.4. Germany
5.3.5. France
5.3.6. UK
5.3.7. Italy
5.3.8. Spain
5.3.9. Rest of Europe

5.4. ASIA-PACIFIC

5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast
5.4.4. Japan
5.4.5. China
5.4.6. India
5.4.7. Australia
5.4.8. South Korea
5.4.9. Rest of Asia-Pacific

5.5. LAMEA

5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast
5.5.4. Brazil
5.5.5. South Africa
5.5.6. Saudi Arabia
5.5.7. Rest of LAMEA

CHAPTER 6 COMPANY PROFILES

6.1. ASTRAZENECA PLC

6.1.1. Company overview
6.1.2. Operating business segments
6.1.3. Business performance
6.1.4. Key strategic moves and developments

6.2. BOEHRINGER INGELHEIM GMBH

6.2.1. Company overview
6.2.2. Operating business segments
6.2.3. Business performance
6.2.4. Key strategic moves and developments

6.3. ELI LILLY AND COMPANY

6.3.1. Company overview
6.3.2. Operating business segments
6.3.3. Key strategic moves and developments

6.4. GLAXOSMITHKLINE PLC

6.4.1. Company overview
6.4.2. Operating business segments
6.4.3. Business performance
6.4.4. Key strategic moves and developments

6.5. JOHNSON & JOHNSON

6.5.1. Company overview
6.5.2. Operating business segments
6.5.3. Business performance
6.5.4. Key strategic moves and developments

6.6. MERCK & CO., INC.

6.6.1. Company overview
6.6.2. Operating business segments
6.6.3. Business performance
6.6.4. Key strategic moves and developments

6.7. NOVARTIS AG

6.7.1. Company overview
6.7.2. Operating business segments
6.7.3. Business performance
6.7.4. Key strategic moves and developments

6.8. NOVO NORDISK

6.8.1. Company overview
6.8.2. Operating business segments
6.8.3. Business performance
6.8.4. Key strategic moves and developments

6.9. SANOFI S.A.

6.9.1. Company overview
6.9.2. Operating business segments
6.9.3. Business performance
6.9.4. Key strategic moves and developments

6.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED

6.10.1. Company overview
6.10.2. Operating business segments
6.10.3. Business performance
6.10.4. Key strategic moves and developments
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll